| Drug Name | ***0130 |
| Description |
A novel antibody-drug conjugate (ADC) targeting stage-specific embryonic antigen 4 (SSEA-4) is being investigated in preclinical studies for cancer therapy. Compared to conventional chemotherapeutic drugs, the ADC targets tumors expressing SSEA-4 and releases cytotoxic payload to directly shrink or eradicate tumors. |
| Target | SSEA-4 |
| Drug Modality | Antibody-Drug Conjugate |
| Indication | Cancer |
| Product Category | Cancer Immunotherapy |
| Mechanism of Action | Targeting SSEA-4 |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |